Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

References

• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590–2594.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119: 1182–1189.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd J, Furman R, et al. Preliminary evidence of clinical activity in a phase I study of CAL-101, a potent selective inhibitor of the p110 delta isoform of phosphatidylinositol-3-kinase, in patients with relapsed or refractory chronic lymphocytic leukemia. Haematologica 2009;94(Suppl. 3):S88.
   Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201–2207.
   PubMed Web of Science ®Google Scholar
• Fowler N, Advani R, Sharman J, et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood 2012;120(Suppl. 1): Abstract 156.
   Web of Science ®Google Scholar
• Wang M, Rule S, Martin P, et al. Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood 2012;120(Suppl. 1): Abstract 904.
   Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676–1679.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Wilson W, Gerecitano J, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012;120(Suppl. 1): Abstract 686.
   Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714–726.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47–52.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365: 2497–2506.
   PubMed Web of Science ®Google Scholar
• Improgo MR, Kiezun A, Wang Y, et al. Functional somatic and germline variants in the NF-κB pathway in chronic lymphocytic leukemia.Blood 2012;120(Suppl. 1): Abstract 560.
   Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120:4684–4691.
   PubMed Web of Science ®Google Scholar
• Byrd J, Furman R, Coutre S, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. Blood 2012;120(Suppl. 1): Abstract 89.
   Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820–2822.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Cymbalista F, Leblond V, et al. Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: updated results from a phase II study of the GCLLSG and FCGCLL/MW. Blood 2012; 120(Suppl. 1): Abstract 716.
   PubMed Web of Science ®Google Scholar
• Brown JR, Barrientos J, Flinn I, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study. Haematologica 2012;97(S1): 218 (abstract 0543).
   Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012;30(15 Suppl.): Abstract 6508.
   Web of Science ®Google Scholar
• Chowdhury O, Varghese A, Pattinson J, et al. Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. Br J Haematol 2011;155:519–521.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Blood 2012;120(Suppl. 1): Abstract 187.
   Web of Science ®Google Scholar
• Hsu J, Gu Y, Tan SL, et al. Bruton's tyrosine kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol Lett 2013;150:97–104.
   PubMed Web of Science ®Google Scholar
• Liu J, Fitzgerald ME, Berndt MC, et al. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006;108:2596–2603.
   PubMed Web of Science ®Google Scholar
• Farooqui M, Lozier JN, Valdez J, et al. Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 2012;120(Suppl. 1): Abstract 1789.
   Web of Science ®Google Scholar
• Herman S, Farooqui M, Bezabhie R, et al. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. Blood 2012;120(Suppl. 1): Abstract 185.
   PubMed Web of Science ®Google Scholar
• Wang YL, Cheng S, Ma J, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Blood 2012;120(Suppl. 1): Abstract 2903.
   Google Scholar
• Farooqui M, Aue G, Valdez J, et al. Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death. Blood 2012;120(Suppl. 1): Abstract 2899.
   Web of Science ®Google Scholar
• Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012;120:3501–3509.
   PubMed Web of Science ®Google Scholar
• Zhang W, Kater AP, Widhopf GF 2nd, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010;107:18956–18960.
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977–2986.
   PubMed Web of Science ®Google Scholar
• Brown JR, Jahn TM, Furman RR, et al. Patterns of nodal response and lymphocytosis in patients with previously treated CLL receving the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101) alone or in combination with rituximab (R) or bendamustine (B). Clin Lymphoma Myeloma Leuk 2011;11(Suppl. 2):S146–S147.
   Google Scholar
• Flinn IW, Horwitz SM, Patel M, et al. Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide- 3-kinase-δ,γ, in patients with advanced hematologic malignancies. Blood 2012;120(Suppl. 1): Abstract 3663.
   Web of Science ®Google Scholar
• Brown JR, Sharman JP, Harb WA, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2012;30(15 Suppl.): Abstract 8032.
   Web of Science ®Google Scholar
• Evans E, Sheets M, Bernard H, et al. Prolonged inhibition of BCR signaling and suppression of B cell lymphoma through irreversible inhibition of Bruton's tyrosine kinase. Blood 2008;112(Suppl. 1): Abstract 2608.
   Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Woyach JA, et al. Ibrutinib is an irreversible molecular inhibitor of interleukin-2 inducible kinase: expanding therapeutic potential and modulating a Th1 selective pressure in CD4 T-Cells. Blood 2012;120(Suppl. 1): Abstract 775.
   Web of Science ®Google Scholar